

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-262

APPROVAL LETTER



NDA 22-262

NDA APPROVAL

Duramed Pharmaceuticals, Inc.
Attention: Joseph A. Carrado, M.Sc., R.Ph.
Vice President, Global Regulatory Affairs
One Belmont Avenue
11th Floor
Bala Cynwyd, PA 19004

Dear Mr. Carrado:

Please refer to your new drug application dated and received December 26, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for LoSeasonique[™] (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).

We acknowledge receipt of your submissions dated March 27, April 3 and 24, June 3, 6, and 20, July 25, August 26, September 5, October 8, 20, 21 (2), and 24, 2008.

This new drug application provides for the use of LoSeasonique[™] tablets for use by women to prevent pregnancy.

CONTENT OF LABELING

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling text for the package insert. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-262."

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the submitted carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*.

Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material.

For administrative purposes, designate this submission "Final Printed Carton and Container Labels for approved NDA 22-262." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with a FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for pre-menarcheal patients because pre-menarcheal patients are not at risk of becoming pregnant and the use of this product before menarche is not indicated. We note that you have fulfilled the pediatric study requirement for post-menarcheal pediatric patients by extrapolation of adult data.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 22-262

Page 3

If you have any questions, please call Pamela Lucarelli, Regulatory Health Project Manager, at (301)-796-3961.

Sincerely,

{See appended electronic signature page}

Scott Monroe, M.D.

Director

Division of Reproductive and Urologic Products

Office of Drug Evaluation III

Center for Drug Evaluation and Research